Viewing Study NCT04825704


Ignite Creation Date: 2025-12-24 @ 7:59 PM
Ignite Modification Date: 2025-12-30 @ 11:35 PM
Study NCT ID: NCT04825704
Status: COMPLETED
Last Update Posted: 2023-08-04
First Post: 2021-03-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Bupivacaine in Tonsillectomy
Sponsor: Nordlandssykehuset HF
Organization:

Study Overview

Official Title: Can Topical Administration of Bupivacaine Reduce Pain After Tonsillectomy?
Status: COMPLETED
Status Verified Date: 2023-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A placebo-controlled and double-blind study is planned according to current legislation and ICH GCP guidelines with 80 patients at Nordland Hospital, Bodø. Fifty percent are randomized to receive bupivacaine 5 mg / ml on the gauze swabs used to stop the bleeding after tonsillectomy, and 50% receive 0.9% sodium chloride.

Pain at rest and pain when swallowing according to numerical rating scale (0-10), as well as the presence of the following symptoms (yes / no): nausea, vomiting, food intake, bleeding, fever, need for extra painkillers in the form of morphine or similar will be registered 1, 2, 3, 4, 5, 6 hours and 1, 2 4 and 6 days after the operation. Differences are analyzed with "mixed models" statistics and the results will be published in a peer-based journal.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: